Bromfenac as Adjunctive Treatment with Intravitreal Bevacizumab in Branch Retinal Vein Occlusion of Macular Edema

Jong Myoung Yun; Young Wook Cho; Jong Won Moon

doi:10.3341/jkos.2020.61.2.183

Journal List > J Korean Ophthalmol Soc > v.61(2) > 1142608

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Yun, Cho, and Moon: Bromfenac as Adjunctive Treatment with Intravitreal Bevacizumab in Branch Retinal Vein Occlusion of Macular Edema

Original Article

Journal of the Korean Ophthalmological Society 2020; 61(2): 183-189.

Published online: 18 February 2020

DOI: https://doi.org/10.3341/jkos.2020.61.2.183

Bromfenac as Adjunctive Treatment with Intravitreal Bevacizumab in Branch Retinal Vein Occlusion of Macular Edema

Jong Myoung Yun, MD, Young Wook Cho, MD, Jong Won Moon, MD

Department of Ophthalmology, Daegu Fatima Hospital, Daegu, Korea.

Address reprint requests to Jong Won Moon, MD. Department of Ophthalmology, Daegu Fatima Hospital, #99 Ayang-ro, Dong-gu, Daegu 41199, Korea. Tel: 82-53-940-7140, Fax: 82-53-954-7417, anantos@naver.com

Received 20 June 2019 Revised 14 October 2019 Accepted 17 January 2020

The Korean Ophthalmological Society

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Purpose

To evaluate the effectiveness of 0.1% topical bromfenac as an adjunctive treatment with intravitreal bevacizumab (IVB) injection for branch retinal vein occlusion (BRVO) patients.

Methods

We retrospectively evaluated 68 eyes of 68 patients with macular edema (ME) secondary to BRVO who were treated with IVB injection and followed up for at least 12 months. Of the 68 eyes, 38 were treated with IVB combined with 0.1% topical bromfenac and 30 were treated with IVB alone. IVB reinjection was performed in cases of recurrence. The primary outcome measurement was the number of IVB injections. Changes in the best-corrected visual acuity (BCVA) and central foveal thickness (CFT) during the 12-month follow-up were compared.

Results

There was no significant difference in the BCVA or CFT between the two groups at the initial and final examinations. However, the number of IVB injections was significantly lower in the 0.1% bromfenac-treated eyes (p < 0.01) than in the control eyes (4.1 ± 0.7 vs. 5.0 ± 0.6 times).

Conclusions

Compared to IVB monotherapy, topical bromfenac as an adjunctive treatment with IVB injection of eyes with ME secondary to BRVO did not affect visual outcomes, but it reduced the number of IVB injections.

Keywords: Bevacizumab, Branch retinal vein occlusion, Macular edema, Nonsteroidal anti-inflammatory drug (NSAIDs)

Figures and Tables

Table 1

Baseline characteristics

Values are presented as mean ± standard deviation unless otherwise indicated. ‘Group A’ is patients treated with IVB alone, ‘Group B’ is patients treated with IVB combined with 0.1% bromfenac ophthalmic solution.

BCVA = best-corrected visual acuity; logMAR = logarithm of minimal angle of resolution; CFT = central foveal thickness; DD = disc diameter; logMAR = logarithm of minimum angle of resolution; SE = spherical equivalent; IVB = intravitreal bevacizumab.

^*Statistical significance was calculated by Mann-Whitney U-test.

Table 2

Comparison of visual acuity, central foveal thickness and number of injections between two groups

Values are presented as mean ± standard deviation. ‘Group A’ is patients treated with IVB alone, ‘Group B’ is patients treated with IVB combined with 0.1% bromfenac ophthalmic solution.

BCVA = best-corrected visual acuity; logMAR = logarithm of minimal angle of resolution; CFT = central foveal thickness; IVB = intravitreal bevacizumab injection alone.

^*Statistical significance was calculated by Mann-Whitney U-test; ^†Wilcoxon signed-rank test.

Table 3

Comparison of period from the improvement of macular edema to reinjection between two groups

Values are presented as mean ± standard deviation. ‘Group A’ is patients treated with IVB alone, ‘Group B’ is patients treated with IVB combined with 0.1% bromfenac ophthalmic solution.

IVB = intravitreal bevacizumab injection alone.

^*Statistical significance was calculated by Mann-Whitney U-test.

Notes

This study was presented as an e-poster at the 121th Annual Meeting of the Korean Ophthalmological Society 2019.

^{Conflicts of Interest} The authors have no conflicts to disclose.

References

1. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010; 117:313–319.e1.

2. Silva RM, Faria de Abreu JR, Cunha-Vaz JG. Blood-retina barrier in acute retinal branch vein occlusion. Graefes Arch Clin Exp Ophthalmol. 1995; 233:721–726.

3. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2006; 244:309–315.

4. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther. 2008; 16:791–799.

5. Kriechbaum K, Michels S, Prager F, et al. Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol. 2008; 92:518–522.

6. Kondo M, Kondo N, Ito Y, et al. Intravitreal injection of bevacizumab for macular edema secondary to branch retinal vein occlusion: results after 12 months and multiple regression analysis. Retina. 2009; 29:1242–1248.

7. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol. 2009; 93:452–456.

8. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 2007; 114:855–859.

9. Smiddy WE. Economic considerations of macular edema therapies. Ophthalmology. 2011; 118:1827–1833.

10. Pinna A, Blasetti F, Ricci GD, Boscia F. Bromfenac eyedrops in the treatment of diabetic macular edema: a pilot study. Eur J Ophthalmol. 2017; 27:326–330.

11. Li S, Hu A, Wang W, et al. Combinatorial treatment with topical NSAIDs and anti-VEGF for age-related macular degeneration, a meta-analysis. PLoS One. 2017; 12:e0184998.

12. Wyględowska-Promieńska D, Piotrowska-Gwóźdź A, Piotrowska-Seweryn A, Mazur-Piotrowska G. Combination of aflibercept and bromfenac therapy in age-related macular degeneration: a pilot study aflibercept and bromfenac in AMD. Med Sci Monit. 2015; 21:3906–3912.

13. Shimura M, Yasuda K. Topical bromfenac reduces the frequency of intravitreal bevacizumab in patients with branch retinal vein occlusion. Br J Ophthalmol. 2015; 99:215–219.

14. Hayreh SS, Zimmerman MB. Fundus changes in branch retinal vein occlusion. Retina. 2015; 35:1016–1027.

15. Munk MR, Sacu S, Huf W, et al. Differential diagnosis of macular edema of different pathophysiologic origins by spectral domain optical coherence tomography. Retina. 2014; 34:2218–2232.

16. Abri Aghdam K, Reznicek L, Soltan Sanjari M, et al. Peripheral retinal non-perfusion and treatment response in branch retinal vein occlusion. Int J Ophthalmol. 2016; 9:858–862.

17. Finkelstein D. Argon laser photocoagulation for macular edema in branch vein occlusion. Ophthalmology. 1986; 93:975–977.

18. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol. 2009; 127:1115–1128.

19. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol. 2005; 140:256–261.

20. Funk M, Kriechbaum K, Prager F, et al. Intraocular concentrations of growth factors and cytokines in retinal vein occlusion and the effect of therapy with bevacizumab. Invest Ophthalmol Vis Sci. 2009; 50:1025–1032.

21. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. 2010; 117:1102–1112.e1.

22. Varma R, Bressler NM, Suñer I, et al. Improved vision-related function after ranibizumab for macular edema after retinal vein occlusion: results from the BRAVO and CRUISE trials. Ophthalmology. 2012; 119:2108–2118.

23. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology. 2011; 118:1594–1602.

24. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology. 2012; 119:802–809.

25. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study. Ophthalmology. 2014; 121:209–219.

26. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. Ophthalmology. 2015; 122:538–544.

27. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol. 2010; 21:178–183.

28. Gomi F, Sawa M, Tsujikawa M, Nishida K. Topical bromfenac as an adjunctive treatment with intravitreal ranibizumab for exudative age-related macular degeneration. Retina. 2012; 32:1804–1810.

29. Baklayan GA, Patterson HM, Song CK, et al. 24-hour evaluation of the ocular distribution of (14)C-labeled bromfenac following topical instillation into the eyes of New Zealand White rabbits. J Ocul Pharmacol Ther. 2008; 24:392–398.

30. Yoshinaga N, Arimura N, Otsuka H, et al. NSAIDs inhibit neovascularization of choroid through HO-1-dependent pathway. Lab Invest. 2011; 91:1277–1290.

TOOLS

Similar articles